DFO
ELVN icon

Duquesne Family Office’s Enliven Therapeutics ELVN Stock Holding History

Duquesne Family Office’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-947,405
Closed -$19.4M – 71
2025
Q3 		$19.4M Buy
947,405
+484,405
+105% +$9.76M 0.48% 50
2025
Q2 		$9.29M Buy
+463,000
New +$8.77M 0.23% 64

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Duquesne Family Office's ELVN Position: Q4 2025 in Review

Duquesne Family Office sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 947,405 shares — an estimated $19.4M sold.

Duquesne Family Office first reported a position in ELVN in Q2 2025 and held it in 2 quarters. The position peaked at $19.4M in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Duquesne Family Office reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Duquesne Family Office sold 947,405 Enliven Therapeutics shares in Q4 2025, an estimated $19.4M.
  • Duquesne Family Office first reported a position in Enliven Therapeutics in Q2 2025 and held it in 2 quarters.
  • Duquesne Family Office's Enliven Therapeutics position peaked at $19.4M in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Duquesne Family Office's 13F filing for Q4 2025, filed 17 Feb 2026.